A Real World Study to Assess the Clinical Features of Skin Toxicities and its Association with Efficacy of Nivolumab or Pembrolizumab in Patients with Advanced Melanoma
Latest Information Update: 08 Jun 2021
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 08 Jun 2021 New trial record